Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Injectable recombinant human collagen hydrogels for prevention of heart failure after myocardial infarction.
FY 2015-16
Summary
In spite of efforts to restore blood flow to the injured heart muscle following a heart attack, 10% of patients will develop heart failure (HF). The majority of these patients will not survive more than five years after HF diagnosis without a heart transplant. After a heart attack stress is placed on the injured heart muscle, the infarct region, before healing of the injury with a stiff collagen scar. The stress results in pathological structural and functional changes in the heart, called ventricular remodeling, which lead to HF. A key contributing factor to the remodeling process is the degredation and subsequent modification of the cardiac extracellular matrix (ECM). A therapeutic strategy with pre-clinical promise is the injection of biomaterials into the infarct region to replace the modified cardiac ECM. The cardiac ECM is a protein network, primarily composed of type I and III collagen fibers, which provides structural support and promotes tissue healing by acting as a bioactive scaffold for cardiac cells. The ideal biomaterial therapy therefore must restore both critical matrix functions for long-term HF prevention. However, few biomaterials tested to date are bioactive and none are of human origin, which can prevent clinical translation. Our research group has developed the first recombinant human collagen type I and type III biomaterials. My proposed research will study the ability of these biomaterials to prevent HF in vivo using a mouse model. My hypothesis is that injection of these biomaterials into the infarct region will preserve heart function by prevention of ventricular remodeling. The results of this study are expected to guide the clinical translation of the first recombinant human collagen biomaterial treatment for HF.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
349934
Name
McLaughlin Sarah
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Injectable recombinant human collagen hydrogels for prevention of heart failure after myocardial infarction.
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomaterials; Echocardiography; Heart Failure Prevention; Human Recombinant Collagen; Injectable Hydrogels; Intramyocardial Injection; Mouse Model Of Mi; Myocardial Infarction; Tissue Regeneration; Ventricular Remodelling
Abstract
In spite of efforts to restore blood flow to the injured heart muscle following a heart attack, 10% of patients will develop heart failure (HF). The majority of these patients will not survive more than five years after HF diagnosis without a heart transplant. After a heart attack stress is placed on the injured heart muscle, the infarct region, before healing of the injury with a stiff collagen scar. The stress results in pathological structural and functional changes in the heart, called ventricular remodeling, which lead to HF. A key contributing factor to the remodeling process is the degredation and subsequent modification of the cardiac extracellular matrix (ECM). A therapeutic strategy with pre-clinical promise is the injection of biomaterials into the infarct region to replace the modified cardiac ECM. The cardiac ECM is a protein network, primarily composed of type I and III collagen fibers, which provides structural support and promotes tissue healing by acting as a bioactive scaffold for cardiac cells. The ideal biomaterial therapy therefore must restore both critical matrix functions for long-term HF prevention. However, few biomaterials tested to date are bioactive and none are of human origin, which can prevent clinical translation. Our research group has developed the first recombinant human collagen type I and type III biomaterials. My proposed research will study the ability of these biomaterials to prevent HF in vivo using a mouse model. My hypothesis is that injection of these biomaterials into the infarct region will preserve heart function by prevention of ventricular remodeling. The results of this study are expected to guide the clinical translation of the first recombinant human collagen biomaterial treatment for HF.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
McLaughlin, Sarah
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~